The chapter delves into the complexities of NAD metabolism, discussing its importance and the role of NR as a key precursor. It touches on human clinical trials concerning NR supplementation, focusing on safety and efficacy. The conversation also highlights the differences in inducing obesity in mice versus humans and the potential impact of NR supplementation on liver health.
Charles Brenner, PhD is the chair of the new Department of Diabetes & Cancer Metabolism at the Beckman Research Institute of the City of Hope National Medical Center. He is a major contributor to work on nicotinamide adenine dinucleotide metabolism, who discovered the eukaryotic nicotinamide riboside (NR) kinase pathway.